

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

Claims 1-15 (canceled)

Claim 16. (Currently amended) A method for detecting ~~at least one or more~~ biological entity entities in a sample, comprising:

- (a) combining one or more nucleic acid sequences in a sample with multiple primers ~~of~~ comprising randomized nucleotide sequences, said randomized sequences being sufficiently randomized to provide nonpreferential start sites for amplification of the sample nucleic acid sequences;
- (b) performing a plurality of cycles of a polymerase chain reaction to randomly amplify the sample nucleic acid sequences, ~~wherein a detectable nucleoside triphosphate is incorporated during amplification to produce detectable amplification products and wherein sequences corresponding and complementary to only the sample nucleic acid sequences are the amplification products; and to produce nucleic acid amplification products,~~
- (c) hybridizing the detectable multiple combining the amplification products ~~to with~~ an array of predetermined nucleic acid sequences; and
- (d) detecting amplification products hybridized to the array.

Claim 17. (Currently amended) The method of Claim 16, wherein ~~the detectable nucleoside triphosphate is labeled a detectable nucleoside triphosphate is incorporated to produce detectable amplification products,~~ further comprising detecting the detectable amplification products hybridized to the array.

Claim 18. (Previously presented) The method of Claim 17, further comprising relating the detected amplification products to at least one biological entity in the sample.

Claim 19. (Previously presented) The method of Claim 16, wherein the primers are four to fifteen nucleotides in length.

Claim 20. (Previously presented) The method of Claim 16, wherein the array of predetermined nucleic acid sequences is immobilized on a surface.

Claim 21. (Previously presented) The method of Claim 17, wherein the detectable amplification products are enzymatically detected.

Claim 22. (Previously presented) The method of Claim 16, wherein the detectable nucleoside triphosphate is biotinylated.

Claim 23. (Previously presented) The method of Claim 16, wherein the detectable nucleoside triphosphate is fluorescently labeled.

Claim 24. (Previously presented) The method of Claim 16, wherein the detectable nucleoside triphosphate is labeled with digoxigenin.

Claim 25. (Previously presented) The method of Claim 16, wherein the detectable nucleoside triphosphate is labeled with radiolabel.

Claim 26. (Previously presented) The method of Claim 20, wherein the surface is an opaque membrane.

Claim 27. (Previously presented) The method of Claim 20, wherein the surface is silica-based.

Claim 28. (Previously presented) The method of Claim 16, wherein the predetermined nucleic acid sequences are at predetermined positions on the array and wherein the nucleic acid sequences at two or more predetermined positions characterize a different biological entity or variant of a biological entity.

Claim 29. (Previously presented) The method of Claim 16, wherein the sample comprises multiple biological entities.

Claim 30. (Previously presented) The method of Claim 16, wherein the biological entity is a pathogen.

Claim 31. (Previously presented) The method of Claim 16, wherein the predetermined nucleic acid sequences are more than 30 nucleotides in length.

Claim 32. (Currently amended) A method for detecting at least one or more biological entity entities in a sample, comprising:

(a) combining one or more nucleic acid sequences in a sample with multiple primers comprising randomized nucleotide sequences, said randomized sequences being sufficiently randomized to provide amplification products having nucleotide sequences of nonpreferential length corresponding and complementary to only the sample nucleic acid sequences;

(b) performing a plurality of cycles of a polymerase chain reaction to randomly amplify the sample nucleic acid sequences, ~~wherein a detectable nucleoside triphosphate is incorporated during amplification to produce detectable nucleic acid amplification products; and,~~

(c) hybridizing the detectable multiple combining the amplification products to with an array of predetermined nucleic acid sequences; and

(d) detecting amplification products hybridized to the array.

Claim 33. (Currently amended) The method of Claim 32, wherein a detectable nucleoside triphosphate is incorporated to produce detectable amplification products, further comprising detecting the detectable amplification products hybridized to the array.

Claim 34. (Previously presented) The method of Claim 33, further comprising relating the detected amplification products to at least one biological entity in the sample.

Claim 35. (Previously presented) The method of Claim 32, wherein the primers are four to fifteen nucleotides in length.

Claim 36. (Previously presented) The method of Claim 32, wherein the array of predetermined nucleic acid sequences is immobilized on a surface.

Claim 37. (Previously presented) The method of Claim 33, wherein the detectable amplification products are enzymatically detected.

Claim 38. (Previously presented) The method of Claim 32, wherein the detectable nucleoside triphosphate is biotinylated.

Claim 39. (Previously presented) The method of Claim 32, wherein the detectable nucleoside triphosphate is fluorescently labeled.

Claim 40. (Previously presented) The method of Claim 32, wherein the detectable nucleoside triphosphate is labeled with digoxigenin.

Claim 41. (Previously presented) The method of Claim 32, wherein the detectable nucleoside triphosphate is labeled with radiolabel.

Claim 42. (Previously presented) The method of Claim 36, wherein the surface is an opaque membrane.

Claim 43. (Previously presented) The method of Claim 36, wherein the surface is silica-based.

Claim 44. (Previously presented) The method of Claim 32, wherein the predetermined nucleic acid sequences are at predetermined positions on the array and wherein the nucleic acid sequences at two or more predetermined positions characterize a different biological entity or variant of a biological entity.

Claim 45. (Previously presented) The method of Claim 32, wherein the sample comprises multiple biological entities.

Claim 46. (Previously presented) The method of Claim 32, wherein the biological entity is a pathogen.

Claim 47. (Previously presented) The method of Claim 32, wherein the predetermined nucleic acid sequences are more than 30 nucleotides in length.

Claim 48. (Currently amended) A method for detecting ~~at least one or more~~ biological entity entities in a sample, comprising:

(a) combining nucleic acid sequences in a sample with multiple primers comprising randomized nucleotide sequences, said randomized sequences being sufficiently randomized such that substantially ~~all sample an entirety of the~~ nucleic acid sequences of a biological entity are represented among ~~multiple~~ amplification products;

(b) performing a plurality of cycles of a polymerase chain reaction to randomly amplify the sample nucleic acid sequences, ~~wherein a detectable nucleoside triphosphate is incorporated during amplification to produce detectable nucleic acid amplification products and wherein sequences corresponding and complementary to only the sample nucleic acid sequences are the multiple amplification products; and,~~

(c) ~~hybridizing the labeled combining the~~ multiple amplification products ~~to with~~ an array of predetermined nucleic acids; and

(d) detecting amplification products hybridized to the array.

Claim 49. (Currently amended) The method of Claim 48 wherein a detectable nucleoside triphosphate is incorporated to produce detectable amplification products, further comprising detecting the detectable amplification products that hybridized to the array.

Claim 50. (Previously presented) The method of Claim 49, further comprising relating the detected amplification products to at least one biological entity in the sample.

Claim 51. (Previously presented) The method of Claim 48, wherein the primers are four to fifteen nucleotides in length.

Claim 52. (Previously presented) The method of Claim 48, wherein the array of predetermined nucleic acid sequences is immobilized on a surface.

Claim 53. (Previously presented) The method of Claim 49, wherein the detectable amplification products are enzymatically detected.

Claim 54. (Previously presented) The method of Claim 48, wherein the detectable nucleoside triphosphate is biotinylated.

Claim 55. (Previously presented) The method of Claim 48, wherein the detectable nucleoside triphosphate is fluorescently labeled.

Claim 56. (Previously presented) The method of Claim 48, wherein the detectable nucleoside triphosphate is labeled with digoxigenin.

Claim 57. (Previously presented) The method of Claim 48, wherein the detectable nucleoside triphosphate is labeled with radiolabel.

Claim 58. (Previously presented) The method of Claim 52, wherein the surface is an opaque membrane.

Claim 59. (Previously presented) The method of Claim 52, wherein the surface is silica-based.

Claim 60. (Previously presented) The method of Claim 48, wherein the predetermined nucleic acids are at predetermined positions on the array and wherein the nucleic acid sequences at two or more predetermined positions characterize a different biological entity or variant of a biological entity.

Claim 61. (Previously presented) The method of Claim 48, wherein the sample comprises multiple biological entities.

Claim 62. (Previously presented) The method of Claim 48, wherein the biological entity is a pathogen.

Claim 63. (Previously presented) The method of Claim 48, wherein the predetermined nucleic acid sequences are more than 30 nucleotides in length.

Claim 64. (Currently amended) The method of Claim 16, wherein substantially all sample an entirety of the nucleic acid sequences of the biological entity are represented among the multiple amplification products.

Claim 65. (Previously presented) The method of Claim 64, further comprising detecting the detectable amplification products that hybridized to the array.

Claim 66. (Previously presented) The method of Claim 65, further comprising relating the detected amplification products to at least one biological entity in the sample.

Claim 67. (Previously presented) The method of Claim 64, wherein the primers are four to fifteen nucleotides in length.

Claim 68. (Previously presented) The method of Claim 64, wherein the array of predetermined nucleic acid sequences is immobilized on a surface.

Claim 69. (Previously presented) The method of Claim 65, wherein the detectable amplification products are enzymatically detected.

Claim 70. (Previously presented) The method of Claim 64, wherein the detectable nucleoside triphosphate is biotinylated.

Claim 71. (Previously presented) The method of Claim 64, wherein the detectable nucleoside triphosphate is fluorescently labeled.

Claim 72. (Previously presented) The method of Claim 64, wherein the detectable nucleoside triphosphate is labeled with digoxigenin.

Claim 73. (Previously presented) The method of Claim 64, wherein the detectable nucleoside triphosphate is labeled with radiolabel.

Claim 74. (Previously presented) The method of Claim 68, wherein the surface is an opaque membrane.

Claim 75. (Previously presented) The method of Claim 68, wherein the surface is silica-based.

Claim 76. (Previously presented) The method of Claim 64, wherein the predetermined nucleic acids are at predetermined positions on the array and wherein the nucleic acid sequences at two or more predetermined positions characterize a different biological entity or variant of a biological entity.

Claim 77. (Previously presented) The method of Claim 64, wherein the sample comprises multiple biological entities.

Claim 78. (Previously presented) The method of Claim 64, wherein the biological entity is a pathogen.

Claim 79. (Previously presented) The method of Claim 64, wherein the predetermined nucleic acid sequences are more than 30 nucleotides in length.

Claim 80. (Currently amended) A method for detecting ~~at least one~~ or more biological entity entities in a sample, comprising:

(a) combining nucleic acid sequences in a sample with multiple primers comprising randomized nucleotide sequences, said randomized sequences being sufficiently randomized to

provide nonpreferential start sites for amplification of the sample nucleic acid sequences such that substantially all sample an entirety of the nucleic acid sequences of the biological entity are represented among multiple amplification products and said multiple amplification products having nucleotide sequences corresponding and complementary to only the sample nucleic acid sequences;

(b) performing a plurality of cycles of a polymerase chain reaction to randomly amplify the sample nucleic acid sequences at each cycle of the polymerase chain reaction, wherein a detectable nucleoside triphosphate is incorporated during amplification to produce detectable multiple nucleic acid amplification products; and,

(c) hybridizing the labeled combining the multiple amplification products to with an array of predetermined nucleic acids sequences; and

(d) detecting amplification products hybridized to the array.

Claim 81. (Currently amended) The method of Claim 80 wherein a detectable nucleoside triphosphate is incorporated, further comprising detecting the detectable amplification products that hybridized to the array.

Claim 82. (Previously presented) The method of Claim 81, further comprising relating the detected amplification products to at least one biological entity in the sample.

Claim 83. (Previously presented) The method of Claim 80, wherein the primers are four to fifteen nucleotides in length.

Claim 84. (Previously presented) The method of Claim 80, wherein the array of predetermined nucleic acid sequences is immobilized on a surface.

Claim 85. (Previously presented) The method of Claim 81, wherein the detectable amplification products are enzymatically detected.

Claim 86. (Previously presented) The method of Claim 80, wherein the detectable nucleoside triphosphate is biotinylated.

Claim 87. (Previously presented) The method of Claim 80, wherein the detectable nucleoside triphosphate is fluorescently labeled.

Claim 88. (Previously presented) The method of Claim 80, wherein the detectable nucleoside triphosphate is labeled with digoxigenin.

Claim 89. (Previously presented) The method of Claim 80, wherein the detectable nucleoside triphosphate is labeled with radiolabel.

Claim 90. (Previously presented) The method of Claim 84, wherein the surface is an opaque membrane.

Claim 91. (Previously presented) The method of Claim 84, wherein the surface is silica-based.

Claim 92. (Previously presented) The method of Claim 80, wherein the predetermined nucleic acids are at predetermined positions on the array and wherein the nucleic acid sequences at two or more predetermined positions characterize a different biological entity or variant of a biological entity.

Claim 93. (Previously presented) The method of Claim 80, wherein the sample comprises multiple biological entities.

Claim 94. (Previously presented) The method of Claim 80, wherein the biological entity is a pathogen.

Claim 95. (Previously presented) The method of Claim 80, wherein the predetermined nucleic acid sequences are more than 30 nucleotides in length.

Claim 96. (Currently amended) A method for detecting at least one or more biological entity entities of a plurality of preselected biological entities potentially present in a sample, comprising:

(a) combining nucleic acid sequences in the sample with multiple primers comprising randomized nucleotide sequences, the randomized sequences being sufficiently randomized to provide nonpreferential start sites for amplification of the sample nucleic acid sequences;

(b) performing a plurality of cycles of a polymerase chain reaction to randomly amplify the sample nucleic acid sequences to produce amplification products; and,

(c) hybridizing the amplification products to an array of predetermined nucleic acid sequences at predetermined positions on the array, wherein the nucleic acid sequences at the predetermined positions characterize at least one of the plurality of preselected biological entities.

Claim 97. (Currently amended) The method of Claim 96, ~~wherein the~~ wherein a detectable nucleoside triphosphate is incorporated ~~during~~ amplification to produce detectable multiple amplification products.

Claim 98. (Previously presented) The method of Claim 96, wherein the method simultaneously detects two or more biological entities.

Claim 99. (Previously presented) The method of Claim 96, wherein the plurality of preselected biological entities is greater than twenty-five.

Claim 100. (Previously presented) The method of Claim 96, wherein the plurality of preselected biological entities is greater than fifty.

Claim 101. (Previously presented) The method of Claim 96, wherein the plurality of preselected biological entities is greater than one hundred.

Claim 102. (Previously presented) The method of Claim 96, wherein the plurality of preselected biological entities is greater than one thousand.

Claim 103. (Previously presented) The method of Claim 96, wherein the nucleic acid sequences at the predetermined positions comprise a continuum of highly conserved to highly specific nucleic acids.

Claim 104. (Previously presented) The method of Claim 96, wherein the method provides information about the biological entity even if identification of the biological entity cannot be ascertained.

Claim 105. (Previously presented) The method of Claim 96, wherein the method provides information on the biological entity including one or more of the following: the kingdom, phylum, class, order, family, genus and species of the biological entity.

Claim 106. (Previously presented) The method of Claim 96, wherein the method provides the ability to extract information resident in a genome of the biological entity.

Claim 107. (Previously presented) The method of Claim 96, wherein the method provides the ability to extract information about antibiotic resistance of the biological entity.

Claim 108. (Previously presented) The method of Claim 96, wherein the method provides the ability to extract information about virulence of the biological entity.

Claim 109. (Previously presented) The method of Claim 96, wherein the method provides the ability to extract information about transmissibility of the biological entity.

Claim 110. (Previously presented) The method of Claim 96, wherein the method provides the ability to extract information about treatment modalities for the biological entity.

Claim 111. (Previously presented) The method of Claim 96, wherein the method detects a genetic alteration in the biological entity.

Claim 112. (Previously presented) The method of Claim 96, wherein the method detects an induced genetic alteration in the biological entity.

Claim 113. (Previously presented) The method of Claim 96, wherein one or more of the predetermined nucleic acid sequences are redundant on the array.

Claim 114. (Previously presented) The method of Claim 96, wherein two or more of the predetermined nucleic acid sequences are overlapping sequences.

Claim 115. (Previously presented) The method of Claim 96, wherein two or more of the predetermined nucleic acid sequences are overlapping sequences of a single biological entity.

Claim 116. (Previously presented) The method of Claim 96, wherein two or more of the predetermined nucleic acid sequences are sub-sequences of each other.

Claim 117. (Previously presented) The method of Claim 96, wherein two or more of the predetermined nucleic acid sequences are nested subset sequences of each other.

Claim 118. (Previously presented) The method of Claim 96, wherein the detectable amplification products are hybridized to the array under high stringency conditions.

Claim 119. (Previously presented) The method of Claim 96, wherein the detectable amplification products are hybridized to the array under low stringency conditions.

Claim 120. (Previously presented) The method of Claim 96, wherein the detectable amplification products are hybridized to the array under hybridization conditions between about 50 and 65 degrees Celsius.

Claim 121. (Previously presented) The method of Claim 96, wherein the primers are four to fifteen nucleotides in length.

Claim 122. (Previously presented) The method of Claim 96, wherein the primers are four to nine nucleotides in length.

Claim 123. (Previously presented) The method of Claim 96, wherein the primers are four to six nucleotides in length.

Claim 124. (Previously presented) The method of Claim 96, wherein the primers are greater than six nucleotides in length.

Claim 125. (Currently amended) A method for obtaining information resident in a genetic code of ~~at least one or more~~ biological entity entities in a sample, comprising:

- (a) combining nucleic acid sequences in the sample with multiple primers comprising randomized nucleotide sequences, the randomized sequences being sufficiently randomized to provide nonpreferential start sites for amplification of the sample nucleic acid sequences;
- (b) performing a plurality of cycles of a polymerase chain reaction to randomly amplify the sample nucleic acid sequences to produce amplification products; and,
- (c) hybridizing the amplification products to an array of predetermined nucleic acid sequences at predetermined positions on the array; and,
- (d) ~~wherein detection of~~ detecting hybridized amplification products on the array provides to obtain genetic information about the biological entity.

Claim 126. (Currently amended) The method of Claim 125, wherein substantially ~~all sample an entirety of the~~ nucleic acid sequences of the biological entity are represented among the ~~multiple~~ amplification products.

Claim 127. (Previously presented) The method of Claim 125, wherein the genetic information characterizes the biological entity.

Claim 128. (Previously presented) The method of Claim 125, wherein the genetic information identifies the biological entity.

Claim 129. (Previously presented) The method of Claim 125 wherein the genetic information monitors the biological entity.

Claim 130. (Previously presented) The method of Claim 125, wherein the genetic information monitors the presence of the biological entity.

Please add the following new claims:

Claim 131. (Newly presented) The method of Claim 16, wherein the randomized sequences are sufficiently randomized to provide multiple amplification products of nonpreferential length.

Claim 132. (Newly presented) The method of Claim 48, wherein the randomized sequences are sufficiently randomized to provide multiple amplification products of nonpreferential length.

Claim 133. (Newly presented) The method of Claim 80, wherein the randomized sequences are sufficiently randomized to provide multiple amplification products of nonpreferential length.

Claim 134. (Newly presented) The method of Claim 96, wherein the randomized sequences are sufficiently randomized to provide multiple amplification products of nonpreferential length.

Claim 135. (Newly presented) The method of Claim 125, wherein the randomized sequences are sufficiently randomized to provide multiple amplification products of nonpreferential length.

Claim 136. (Newly presented) The method of Claim 17, wherein the detectable nucleoside triphosphate is incorporated during amplification.

Claim 137. (Newly presented) The method of Claim 33, wherein the detectable nucleoside triphosphate is incorporated during amplification.

Claim 138. (Newly presented) The method of Claim 49, wherein the detectable nucleoside triphosphate is incorporated during amplification.

Claim 139. (Newly presented) The method of Claim 81, wherein the detectable nucleoside triphosphate is incorporated during amplification.

Claim 140. (Newly presented) The method of Claim 97, wherein the detectable nucleoside triphosphate is incorporated during amplification.